# Presentation: 231597

## Countermeasure Inventory Tracking (CIT) Initiative

- Jeanne Tropper, MS, MPH
- September 04, 2007
- Division of Emergency Preparedness and Response
- National Center for Public Health Informatics
- Centers for Disease Control and Prevention

## Objectives of Meeting

- Familiarize HHS with CRA and its inventory component
- Determine how CDC can capitalize on the HHS relationship with Roche and others to obtain inventory data needed for situational awareness and response planning
- Explore the need for related data collection and access between HHS and CDC

## What is CRA?

- As a* program,* includes the people, processes and tools to increase public health capabilities while supporting federal reporting requirements to monitor and track countermeasures pre-event, event, post-event

**Countermeasure & Response Administration (CRA)**

***Selected *****Priority Countermeasures in the Commercial Sector**
**Complementary to  other CDC Activities: **
**Vaccine Tracking (NCIRD VODS)**
**Federal Stockpile (SNS Inventory)**

***Any***** Countermeasure,  any Event**
**Detail Data Collection**
**Aggregate Reporting**

**Liaison with PH Partners, PHIN Help Desk, DAMC SMEs, DSLR SMEs, SNS**

**Program within NCPHI/DEPR**

## Countermeasure and Response Administration – Inventory Tracking

- A national program to help federal and state emergency response authorities locate critical medical countermeasures during public health emergencies.

*CRA Inventory Tracking initiative is sponsored by the **Centers for Disease Control and Prevention*

**Notes:**
Main Purpose: To provide a concise definition of CIT to frame the discussion

## CIT Operational Concept

- Ordering
- Customers

**PRODUCT FLOW**

**Manufacturers**

**Distributors**

- DATA FLOW

**CDC Data****Mart**

**Emergency****Planning ****and Response**

**   ****Filtered Data**

- ManufacturerInventory and Shipment Data

- DistributorInventory and Shipment Data

**SAP**

**Notes:**
Main Purpose: To illustrate the flow of data to CIT at different points in the supply chain and the overall architecture
Issue: Filter data at source or at after EDI?

## Target Countermeasures

- Pandemic Influenza
- Oseltamivir phosphate (Tamiflu®)
- Zanamivir (Relenza®)
- Bioterrorism and Infectious Diseases
- Ciprofloxacin – *Anthrax, Tularemia, Plague*
- Doxycycline – *Anthrax, Tularemia, Plague*
- Levofloxacin (Levaquin®) – *Anthrax*
- Streptomycin –*Tularemia, Plague*
- Gentamicin – *Tularemia, Plague, Botulism*
- Additional antibiotics
- Selected Medical Materials

**Notes:**
Main Purpose: To identify the items to be accounted for in the system, and highlight the initial importance of influenza medications

## Basic Data Requirements for CIT

- Product Information
- National Drug Code numbers and descriptions
- Unit of measure/packaging
- Lot number and expiration date
- Inventory Data
- Quantities on hand, in process/on order, commitments
- Shipments
- Purchase order number
- Shipping information and status
- Recipient identifier/type and location (zip code)

*No financial information will be requested!*

**Notes:**
Main Purpose: To identify the data that are requested in general terms
Note – some are one-time items that will not be part of the data feed (i.e., NDC descriptions)

## Questions about Dashboard Report

- Who are the report compilers and consumers?
- What is the source of Treatment Course quantities needed?
- Are “Treatment Courses Due for delivery” on order or in transit?

## Questions about DHHS Data Sources

- Who are the primary sources for Antiviral data?
- Who is the POC at each data source?
- Who committed the organization to be a data source?
- Are data use agreements in place?
- What are the characteristics of the data source communications?
- Media
- Standards and protocols
- File formats and data elements
- What are plans (if any) for expanding the number of participants?

## Questions about Business Operations

- What contractual vehicles/purchasing provisions exist for antivirals?
- How does HHS synch demand with the manufacturers?

## Current Status of CIT

- Data Source Recruitment
- Cycle 1 underway
- Meeting with priority Data Source targets, leveraging CDC/HHS relationships where appropriate
- 2 anti-viral manufacturers
- Top 3 distributors by volume
- Industry associations
- Selecting targets for Cycle 2

## Current Status (continued)

- SAP Demonstration System
- Synchronized with Pan Flu exercise
- Demos for requirements elicitation and refinement
- Technical Assessments
- Requirements for V1.0
- Data Model
- Connectivity Modes, Protocols, Data Mapping

## CIT Demonstration(Screen Shots from Demo)

## How Much Antiviral Stock is in the Commercial Supply Chain?

- Notional Data – for Demo Only

## What are the Availability Characteristics of Antivirals in the Supply Chain?

- Notional Data – for Demo Only

## What Pan Flu Antivirals are Available in a Specific Area?

- Notional Data – for Demo Only

## Where have Pan Flu Antivirals Been Delivered?

- Notional Data – for Demo Only

## What is the Scope of the Initial CIT System?

- Notional Data – for Demo Only